Close mobile menu×
Close mobile menu

Murty Vundavalli, PhD

Board Certifications: 
Clinical Genetics and Genomics (MD)
Accepting New Patients
Profile Headshot

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Clinical Genetics and Genomics (MD)

Clinical Expertise

  • Karyotyping
  • Cancer Genetics
  • Laboratory Based Translational Research
  • Hematologic Malignancy
  • Molecular Diagnostics: Multiplex Amplification
  • Cytogenetic Study

Education & Training

  • University of Delhi

Honors & Awards

World Health Organization Fellow, Laboratory of Cancer Cytogenetics, Memorial Sloan Kettering Cancer Center, New York (1984-1985).

About Murty Vundavalli

Academic Titles

  • Associate Professor of Pathology at NewYork-Presbyterian/Columbia University Medical Center (in the Institute for Cancer Genetics)

Committee/Societies/Council Memberships

Member -- American Society of Human Genetics

Member -- American Association for Cancer Research, Inc.

Member—American Society of Hematology

Associate Editor (2005-2009), Executive Editor (2009-present), Molecular Cancer

Member, TCGA analysis working group on testicular germ cell tumor, 2015

 Editor: Henry Stewart Talks: Cancer Genetics Series, 2016.

Scientific Advisory Board Member, Cancer Genetics, Inc, 2016

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Languages

  • Hindi
  • Telugu

Gender

  • Male

Research

Our laboratory is interested in understanding the genetic and epigenetic basis of cervical cancer and hematologic malignancies. One of the major goals is to make attempts to identify prognostic markers of response to treatment. 

Carcinoma of uterine cervix is a common malignancy among women worldwide. Most cervical cancers are preceded by distinct preneoplastic epithelial changes providing opportunities to study genetic alterations at an early stage of transformation. Our genome-wide search for genetic and epigenetic alterations has identified several sites of copy number alterations, gene amplifications, and specific genetic pathways in invasive cancer. We are currently evaluating a predictive biomarker of apoptotic response to stratify patients that benefit combination drug therapy.  

In leukemia and lymphoma, a similar strategy is applied to identify genetic and epigenetic predictive markers of response to treatment.  Preclinical validations of a number of epigenetically inactivated markers are underway.

Grants

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

CORE B (Federal Gov)

Apr 1 2014 - Mar 31 2019

Selected Publications

  1. Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC, Parsons R. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov. 2017 Mar 2. doi: 10.1158/2159-8290.CD-16-0612. [Epub ahead of print] PMID: 28255082
  2. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Zhang L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 31: 625-636, 2017. PMID 27568520
  3. Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. 7:37636-37648, 2016.
  4. Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G. The genetic landscape of dural marginal zone lymphomas. Oncotarget. 7:43052-43061, 2016.
  5. Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000471.
  6. Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer. 55(2):177-89, 2016. PMID: 26542757
  7. Shi D, Murty VV, Gu W. PCDH10, a novel p53 transcriptional target in regulating cell migration. Cell Cycle. 14: 857-866, 2015. PMID: 25590240
  8. Gindin T, Murty V, Alobeid B, Bhagat G. MLL/KMT2A translocations in diffuse large B-cell lymphoma. Hematol Oncol 33:239-46, 2015.  PMID: 25131304
  9. Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil Del Alcazar CR, Ilcheva M, Mukherjee B, McEllin B, Vemireddy V, Hatanpaa K, Story MD, Habib AA, Murty VV, Bachoo R, Burma S. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 34: 1064-1072, 2015. PMID: 24632607
  10. Islam MA, Thomas SD, Murty VV, Sedoris KJ, Miller DM. c-Myc quadruplex-forming sequence Pu-27 induces extensive damage in both telomeric and non-telomeric regions of DNA. J Biol Chem. 289(12):8521-31, 2014. PMID: 24464582
  11. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature. 506: 240-244, 2014. PMID: 24429522
  12. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi D, Tabbò F, Ponzoni M, Chadburn A, Murty VV, Bhagat G, Gaidano G, Inghirami G, Malek SN, Rabadan R, Dalla-Favera R. Genetics of Follicular Lymphoma Transformation. Cell Rep. 6:130-40, 2014. PMID:24388756
  13. Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi SC, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler DA, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts KG, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 45:1226-1231, 2013.
  14. Narayan G, Xie D, Freddy AJ, Ishdorj G, Satwani P, Liyanage H, Clark L, Kisselev S, Nandula SV, Scotto L, Alobeid B, Savage D, Tycko B, O’Connor OA, Bhagat G, Murty VV.. PCDH10 Promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer  52: 1030-1041, 2013.
  15. Narayan G, Freddy AJ,Xie D,Liyanage H, Clark L, Kisselev S, Kang JU,  Nandula SV, McGuinn C, Subramaniyam S, Alobeid B,  Satwani P,  Savage D, Bhagat G, Murty  VV. Promoter Methylation-Mediated Inactivation of PCDH10 in Acute Lymphoblastic Leukemia Contributes to Chemotherapy Resistance. Genes, Chromosomes and Cancer 50: 1043-1053, 2011.